5 results
To obtain more information about the efficacy and tolerability of AD 923 in long-term management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids and receive therapy for BTP.
To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids.
Primary Objective:To evaluate the efficacy potential, safety and tolerability of intravenously administered ANXV, in ascending doses, and two different dosing regimens, in patients with confirmed moderate to severe COVID-19.Secondary Objectives:To…
Primary objectives:1) To evaluate the safety of CHMI-trans protocols in healthy malaria-naïve volunteers challenged with Plasmodium falciparum by sporozoite challenge and blood stage challenge. 2) To assess gametocyte infectiousness for Anopheles…
The primary objectives1. To assess the safety and tolerability of intravenous tracer administration of ANXV-800CW in up to three doses (0.5 mg, 1.0 mg, 2.0 mg flat dose) in patients with RVO and/or DR2. To determine the feasibility of molecular…